Analgesic and antipruritic composition, analgesic and antipruritic solution, preparation method and use thereof

Abstract

The present invention discloses an analgesic and antipruritic composition, an analgesic and antipruritic solution, and a preparation method and use thereof. An analgesic and antipruritic composition, the composition comprises a first active ingredient, a second active ingredient and a third active ingredient, the first active ingredient is a Hamamelis extract, the second active ingredient is an anti-allergic agent, the anti-allergic agent is selected from one or more of a Panax notoginseng extract, a honeysuckle extract and a chamomile extract; the third active ingredient is a cooling agent, the cooling agent is selected from one or two of menthol and menthol lactate, and the fourth active ingredient is allantoin; the mass ratio of the first active ingredient, the second active ingredient, the third active ingredient and the fourth active ingredient is (10-30): (5-15): (1-3): (2-4). The first active ingredient, the second active ingredient, the third active ingredient and the fourth active ingredient of the present invention can synergistically improve the antipruritic and analgesic effects.

Description

Technical Field

[0001] The invention belongs to the technical field of daily cosmetics, and specifically relates to a pain-relieving and antipruritic composition, a pain-relieving and antipruritic solution, and a preparation method and use thereof. Background Art

[0002] Currently, the post-toilet cleaning products on the market are mainly toilet paper and the wet toilet paper that has become popular in recent years. The disadvantage of toilet paper is that it often cannot thoroughly clean the fecal residues around the anus, and the experience is poor; wet toilet paper is another general product for post-toilet cleaning. It uses soft non-woven fabric as a carrier, and its solution components are mainly disinfectants and antibacterial agents. Its main function is to more thoroughly clean the fecal residues around the anus and disinfect and inhibit bacteria. The above two products can meet the general population's needs for post-toilet cleaning, but their active ingredients have no effective care effects on anorectal diseases, such as antibacterial and anti-inflammatory effects. Patients with small anorectal diseases and those after surgery, as well as those exposed to high-risk factors for hemorrhoids such as long-term sitting, long-term standing, and pregnancy require additional cleaning and care measures. Summary of the invention

[0003] In order to overcome the problems existing in the prior art, the purpose of the present invention is to provide an analgesic and antipruritic composition, an analgesic and antipruritic solution, and a preparation method and use thereof.

[0004] In order to achieve the above-mentioned purpose and other related purposes, the present invention adopts the following technical solutions:

[0005] One of the purposes of the present invention is to protect an analgesic and antipruritic composition, the composition comprising a first active ingredient, a second active ingredient, a third active ingredient and a fourth active ingredient.

[0006] The first active ingredient is Hamamelis virginiana extract,

[0007] The second active ingredient is an anti-allergic agent, which is selected from one or more of Panax notoginseng extract, honeysuckle extract and chamomile extract.

[0008] The third active ingredient is a cooling agent, and the cooling agent is selected from one or both of menthol and menthol lactate.

[0009] The fourth active ingredient is allantoin,

[0010] The mass ratio of the first active ingredient, the second active ingredient, the third active ingredient and the fourth active ingredient is (10-30): (5-15): (1-3): (2-4).

[0011] The witch hazel extract of the present invention contains tannin, which has a healing effect, can shrink the skin, help stop bleeding, soothe irritated allergic skin, and has calming, anti-inflammatory, anti-allergic, soothing and astringent effects; the coffee tannic acid contained in the honeysuckle extract has strong antibacterial, fat-reducing, skin-beautifying and anti-aging effects, and the luteolin contained in the honeysuckle extract has antibacterial and anti-inflammatory effects, strong skin penetration, can eliminate free radicals, and has the function of absorbing ultraviolet rays; the chamomile extract has analgesic, soothing, antibacterial and wound healing effects; the Panax notoginseng extract not only has good hemostatic and blood-activating and blood-stasis-removing bidirectional pharmacological effects, but also has obvious blood-tonifying effects, can promote the division and growth of various blood cells such as red blood cells, white blood cells, platelets, etc. in the blood, increase the number, and maintain a normal level; menthol and menthol lactate are flavoring agents, which are cooling and itching-relieving; and allantoin can soften tissues and promote wound healing.

[0012] Preferably, the mass ratio of the first active ingredient, the second active ingredient, the third active ingredient and the fourth active ingredient may be (15-25):(8-12):(1-3):(2-4). In a preferred embodiment, it is 20:10:2:3.

[0013] Preferably, the anti-allergic agent is a mixture of Panax notoginseng extract, Honeysuckle extract and Chamomile extract.

[0014] More preferably, the mass ratio of the Panax notoginseng extract, the honeysuckle extract and the chamomile extract is (1.5-8): (2-10): 1. In a preferred embodiment, it is 3:5:2, 4:5:1, 4:4:2, 2:6:2 and 3:5:2.

[0015] Preferably, the cooling agent is selected from menthol.

[0016] Preferably, the composition further comprises a bactericidal disinfectant; based on the total mass of the composition, the content of the bactericidal disinfectant is 1-5%. Preferably, the content of the bactericidal disinfectant can be 1-3%, 2-4%, or 3-5%. In a preferred embodiment, it is 3.81%.

[0017] More preferably, the bactericidal disinfectant is selected from one or both of benzalkonium chloride and didecyldimethylammonium chloride.

[0018] Further preferably, the bactericidal disinfectant is benzalkonium chloride.

[0019] Preferably, the composition further comprises a preservative; based on the total mass of the composition, the content of the preservative is 2-10%. Preferably, the content of the preservative can be 2-6%, 5-8%, or 7-10%. In a preferred embodiment, it is 3.81%.

[0020] More preferably, the preservative is selected from one or more of phenoxyethanol and iodopropynyl butylcarbamate.

[0021] More preferably, the mass ratio of phenoxyethanol to iodopropynyl butyl carbamate is (0.5-2): 1. Preferably, it can be (0.5-0.9): 1, or (0.8-1.5): 1, or (1.4-2): 1. In a preferred embodiment, it is 10:7.

[0022] Preferably, the composition further comprises a moisturizer; based on the total mass of the composition, the content of the moisturizer is 10-30%. Preferably, the content of the moisturizer can be 10-21%, 18-26%, or 25-30%. In a preferred embodiment, it is 16.2%.

[0023] More preferably, the moisturizer is selected from one or more of ethylhexylglycerin, trimethylglycine, propylene glycol and betaine.

[0024] Further preferably, the moisturizer is selected from a mixture of ethylhexylglycerin, trimethylglycine and propylene glycol.

[0025] More preferably, the mass ratio of ethylhexylglycerol, trimethylglycine and propylene glycol is 1:(2-6):(8-14). Preferably, the mass ratio can be 1:(2-4):(8-14), or 1:(3-5):(8-14), or 1:(4-6):(8-14). In a preferred embodiment, it is 1:4:12.

[0026] Preferably, the composition further comprises a solubilizer; based on the total mass of the composition, the content of the solubilizer is 1 to 10%. Preferably, the content of the solubilizer can be 1 to 4%, or 3 to 8%, or 6 to 10%. In a preferred embodiment, it is 5.72%.

[0027] More preferably, the solubilizing agent is selected from one or more of Tween 20, PEG-20 hydrogenated castor oil, PEG-40 hydrogenated castor oil and PEG-60 hydrogenated castor oil.

[0028] Further preferably, the solubilizing agent is PEG-40 hydrogenated castor oil.

[0029] Preferably, the composition further comprises a defoamer; based on the total mass of the composition, the content of the defoamer is 0.01% to 0.5%. Preferably, the content of the solubilizer can be 0.01% to 0.12%, or 0.1% to 0.3%, or 0.2% to 0.5%. In a preferred embodiment, it is 0.09%.

[0030] Preferably, the defoaming agent is selected from AFE1520.

[0031] Preferably, the composition further comprises a surfactant; based on the total mass of the composition, the content of the surfactant is 0.5-2%. Preferably, the content of the solubilizer can be 0.5-1.2%, or 0.8-1.5%, or 1.3%-2%. In a preferred embodiment, it is 0.9%.

[0032] Preferably, the surfactant is selected from cetylpyridinium chloride.

[0033] Preferably, based on the total mass of the composition, the content of the first active ingredient is not less than 35%.

[0034] Preferably, based on the total mass of the composition, the content of the second active ingredient is not less than 20%.

[0035] Preferably, based on the total mass of the composition, the content of the third active ingredient is not less than 3%.

[0036] Preferably, based on the total mass of the composition, the content of the fourth active ingredient is not less than 5%.

[0037] The second object of the present invention is to protect an analgesic and antipruritic solution prepared by dissolving the composition as described above in water.

[0038] Preferably, the first active ingredient accounts for 2-3% of the total mass of the solution. More preferably, it can be 2-2.8%, or 2.5-3%. In a preferred embodiment, it is 2%.

[0039] Preferably, the second active ingredient accounts for 1 to 1.5% of the total mass of the solution. Preferably, it can be, or can be, or can be. In a preferred embodiment, it is 1%.

[0040] Preferably, the third active ingredient accounts for 0.2-0.6% of the total mass of the solution. More preferably, it can be 0.2-0.4%, or 0.3-0.5%, or 0.4-0.6%. In a preferred embodiment, it is 0.2%.

[0041] Preferably, the fourth active ingredient accounts for 0.3-0.5% of the total mass of the solution. More preferably, it can be 0.3-0.42%, or 0.38-0.55%, or 0.50-0.6%. In a preferred embodiment, it is 0.3%.

[0042] Preferably, the solution further comprises a bactericidal disinfectant, which accounts for 0.1-0.3% of the total mass of the solution. Preferably, the content of the humectant can be 0.1-0.15%, 0.1-0.25%, or 0.22-0.3%. In a preferred embodiment, it is 0.2%.

[0043] More preferably, the bactericidal disinfectant is selected from one or both of benzalkonium chloride and didecyldimethylammonium chloride.

[0044] Further preferably, the bactericidal disinfectant is benzalkonium chloride.

[0045] Preferably, the solution further comprises a preservative, and the preservative accounts for 0.1-0.6% of the total mass of the solution. Preferably, the content of the preservative can be 0.1-0.3%, can be 0.2-0.4%, can be 0.3-0.6%. In a preferred embodiment, it is 0.4%.

[0046] More preferably, the preservative is selected from one or more of phenoxyethanol and iodopropynyl butylcarbamate.

[0047] More preferably, the mass ratio of phenoxyethanol to iodopropynyl butyl carbamate is (0.5-2): 1. Preferably, it can be (0.5-1.2): 1, (1.0-1.8): 1, or (1.5-2): 1. In a preferred embodiment, it is 10:7.

[0048] Preferably, the solution further comprises a moisturizer, and the moisturizer accounts for 0.4-1.2% of the total mass of the solution. Preferably, the content of the moisturizer can be 0.4-0.8%, can be 0.6-1.0%, can be 0.8-1.2%. In a preferred embodiment, it is 0.85%.

[0049] More preferably, the moisturizer is selected from one or more of ethylhexylglycerin, trimethylglycine, propylene glycol and betaine.

[0050] Further preferably, the moisturizer is selected from a mixture of ethylhexylglycerin, trimethylglycine and propylene glycol.

[0051] More preferably, the mass ratio of ethylhexylglycerol, trimethylglycine and propylene glycol is 1:(2-6):(8-14). Preferably, the mass ratio can be 1:(2-4):(8-14), or 1:(3-5):(8-14), or 1:(4-6):(8-14). In a preferred embodiment, it is 1:4:12.

[0052] Preferably, the solution further comprises a solubilizer, and the solubilizer accounts for 0.1-0.6% of the total mass of the solution. Preferably, it can be 0.1%-0.3%, or 0.2%-0.5%, or 0.4%-0.6%. In a preferred embodiment, it is 0.3%.

[0053] More preferably, the solubilizing agent is selected from one or more of Tween 20, PEG-20 hydrogenated castor oil, PEG-40 hydrogenated castor oil and PEG-60 hydrogenated castor oil.

[0054] Further preferably, the solubilizing agent is PEG-40 hydrogenated castor oil.

[0055] Preferably, the solution further comprises a defoamer, and the defoamer accounts for 0.001% to 0.01% of the total mass of the solution. Preferably, it can be 0.001% to 0.005%, or 0.003% to 0.008%, or 0.005% to 0.01%. In a preferred embodiment, it is 0.005%.

[0056] More preferably, the defoaming agent is selected from silicone defoaming agents.

[0057] Further preferably, the organosilicon defoamer is purchased from AFE-1520 defoamer of Dow Corning Corporation of the United States.

[0058] Preferably, the solution further comprises a surfactant, and the surfactant accounts for 0.01% to 0.1% of the total mass of the solution. Preferably, it can be 0.01% to 0.05%, or 0.03% to 0.08%, or 0.05% to 0.1%. In a preferred embodiment, it is 0.05%.

[0059] More preferably, the surfactant is selected from cetylpyridinium chloride.

[0060] Preferably, the solution further comprises a pH adjuster, and the pH adjuster is used to adjust the pH value of the solution to 4.5-6.7.

[0061] More preferably, the pH adjuster is selected from citric acid.

[0062] The third object of the present invention is to protect the preparation method of the analgesic and antipruritic solution as described above, comprising the following steps:

[0063] 1) mixing water and defoamer according to the raw material ratio to obtain a primary mixed solution;

[0064] 2) mixing a preservative, a moisturizer, a third active ingredient, and a solubilizer with the primary mixed solution to obtain a secondary mixed solution;

[0065] 3) Mixing the surfactant, the bactericidal disinfectant, the first active ingredient, the second active ingredient and the fourth active ingredient with the secondary mixed solution, and adjusting the pH value with a pH adjuster to obtain the analgesic and antipruritic solution.

[0066] The fourth object of the present invention is to protect the use of the composition as described above or the analgesic and antipruritic solution as described above as a raw material in the preparation of wet wipes.

[0067] The fifth object of the present invention is to protect a wet wipe, which comprises the composition as described above or the analgesic and antipruritic solution as described above and a wet wipe carrier.

[0068] Preferably, the wet wipes carrier is any one of non-woven fabric, cotton cloth, gauze, and flushable paper.

[0069] More preferably, the wet wipe carrier is flushable paper. The flushable paper of the present invention is a disposable sanitary nonwoven material that can be directly thrown into the toilet to disperse and degrade, and complies with "GB / T40181-2021 Flushability Test Method and Evaluation of Disposable Sanitary Nonwoven Materials".

[0070] Preferably, the mass ratio of the analgesic and antipruritic solution to the wet wipes carrier is (1-3):1.

[0071] More preferably, the mass ratio of the analgesic and antipruritic solution to the wet wipes carrier may be (1-2):1, (1.5-2.5):1, or (2-3):1. In a preferred embodiment, it is 2.5:1.

[0072] The analgesic and antipruritic composition of the present invention comprises: witch hazel having astringent, anti-allergic and calming effects; Panax notoginseng extract having hemostatic, anti-inflammatory and analgesic effects; honeysuckle extract having dampness-dispersing, swelling-removing, toxin-dispersing and antibacterial and anti-inflammatory effects; chamomile extract having soothing, analgesic and tissue-strengthening and edema-eliminating effects; menthol and menthol lactate having cooling, antipruritic and pain-relieving effects; and allantoin having tissue-softening and wound-healing-promoting effects, so that the first active ingredient, the second active ingredient, the third active ingredient and the fourth active ingredient synergistically improve the antipruritic and analgesic effects.

[0073] Compared with the prior art, the present invention has the following beneficial effects:

[0074] 1) After the analgesic and antipruritic composition of the present invention is prepared into an analgesic and antipruritic solution, the wet wipes prepared with a wet wipe carrier have been found through clinical trials to have good analgesic and antipruritic effects on patients with anorectal diseases and individuals prone to hemorrhoids, and have good nursing effects.

[0075] 2) The wet wipes formed by the analgesic and antipruritic combination of the present invention can be individually packaged for easy carrying; deep cleaning can be achieved even without water washing conditions. DETAILED DESCRIPTION

[0076] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are intended to describe specific embodiments, rather than to limit the scope of protection of the present invention. The test methods in the following examples without specifying specific conditions are generally carried out under conventional conditions or under conditions recommended by the manufacturers.

[0077] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any methods, equipment, and materials of the prior art similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention can also be used to realize the present invention.

[0078] Unless otherwise stated, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt conventional techniques in the technical field and related fields.

[0079] Hamamelis virginiana extract was purchased from Yizhan (Shanghai) Chemicals Co., Ltd.

[0080] Panax notoginseng extract, honeysuckle extract and chamomile extract were purchased from Yizhan (Shanghai) Chemicals Co., Ltd.

[0081] Menthol was purchased from Yizhan (Shanghai) Chemicals Co., Ltd.

[0082] The defoamer was AFE-1520, purchased from Yizhan (Shanghai) Chemicals Co., Ltd.

[0083] The model of PEG-40 hydrogenated castor oil is Co40, which was purchased from Yizhan (Shanghai) Chemicals Co., Ltd.

[0084] Iodopropynyl butyl carbamate, model IPBC-6, purchased from Yizhan (Shanghai) Chemicals Co., Ltd. Example 1-4

[0085] Referring to the formula shown in Table 1, a pain-relieving and antipruritic composition was obtained, and a pain-relieving and antipruritic solution was prepared.

[0086] The preparation method of the analgesic and antipruritic composition comprises the following steps:

[0087] 1) Mix water and defoamer according to the formula table to obtain a primary mixed solution;

[0088] 2) mixing a preservative, a moisturizer, a third active ingredient, and a solubilizer with the primary mixed solution to obtain a secondary mixed solution;

[0089] 3) Mixing the surfactant, the bactericidal disinfectant, the first active ingredient, the second active ingredient and the fourth active ingredient with the secondary mixed solution, and adjusting the pH value with a pH adjuster to obtain an analgesic and antipruritic solution.

[0090] Wet wipes: The analgesic and antipruritic solution obtained in Examples 1-4 and the wet wipe carrier are mixed in a mass ratio of 2.5:1 to prepare wet wipes. The wet wipe carrier is flushable paper, the size of the flushable paper is 16cm*18cm, the weight is 60g, the liquid absorption is 2.5 times, and the liquid absorption of each piece is 4.3-4.4g. If the water content is too high, it will easily rot, and if it is too low, it will not be fully soaked. The liquid absorption test method is carried out with reference to "GB / T15979-2002 Hygiene Standards for Disposable Sanitary Products".

[0091] The preparation method of the wet wipes is as follows: the flushable paper is immersed in a pain-relieving and itching-relieving solution to obtain the wet wipes.

[0092] Comparative Example 1

[0093] The difference between Comparative Example 1 and Example 1 is that no Hamamelis extract is added, and the rest of the formula and process are exactly the same. The formula is shown in Table 1.

[0094] Comparative Example 2

[0095] The difference between Comparative Example 2 and Example 1 is that menthol is not added, and the rest of the formula and process are exactly the same. The formula is shown in Table 1.

[0096] Comparative Example 3

[0097] The difference between Comparative Example 3 and Example 1 is that no anti-allergic agent is added, and the rest of the formula and process are exactly the same. The formula is shown in Table 1.

[0098] Comparative Example 4

[0099] The difference between Comparative Example 4 and Example 1 is that the anti-allergic agent contains only Panax notoginseng extract and Honeysuckle extract, and the rest of the formula and process are exactly the same. The formula is shown in Table 1.

[0100] Comparative Example 5

[0101] The difference between Comparative Example 5 and Example 1 is that the anti-allergic agent contains only honeysuckle extract and chamomile extract, and the rest of the formula and process are exactly the same. The formula is shown in Table 1.

[0102] Comparative Example 6

[0103] The difference between Comparative Example 6 and Example 1 is that the anti-allergic agent contains only Panax notoginseng extract and chamomile extract, and the rest of the formula and process are exactly the same. The formula is shown in Table 1.

[0104] Table 1

[0105]

[0106]

[0107] Application Examples

[0108] The wet wipes obtained in Examples 1-5 and Comparative Examples 1-6 were subjected to clinical effect experiments, and the itching and pain levels of the patients were evaluated using questionnaires. The itching scores are shown in Table 2, and the pain scores are shown in Table 3.

[0109] There are 6 patients in each example and comparative example.

[0110] Pruritus was scored as follows:

[0111] 0 degree: basically no itching.

[0112] Grade I (mild): Slight itching, which can be relieved by stroking and patting without scratching. There is no secondary rash caused by scratching.

[0113] Grade II (moderate): Obvious itching, the patient cannot help scratching, and mild secondary rash caused by scratching may be seen.

[0114] Grade III (severe): Severe itching, affecting sleep and work, and obvious secondary rash caused by scratching can be seen locally.

[0115] Grade IV (extremely severe): severe itching, affecting sleep and work, emotional distress, and secondary rashes are severe and numerous.

[0116] Pain was scored as follows:

[0117] 0-2 points: No anal discomfort.

[0118] 3-4 points: Mild pain, mostly intermittent pain, which does not affect normal life.

[0119] 5-6 points: severe pain, which may be persistent but does not significantly affect normal life.

[0120] 7-10 points: The pain is obvious and significantly affects normal life.

[0121] Table 2

[0122]

[0123]

[0124] Table 3

[0125]

[0126] As can be seen from Table 2, the patients used the wet wipes obtained in Example 3 of the present invention, and the patients reported that there was no itching after use; when the patients used the wet wipes obtained in Example 1 of the present invention, only one patient reported itching, but the itching score was 0, and there was no itching; in Example 2 and Example 4, the results were the same as those in Example 1, and only one patient reported itching, but the scores were all I degree, slightly itchy, and scratching was not required, and it could be relieved by stroking and patting, without secondary rash caused by scratching; while in Comparative Examples 1-6, multiple patients had itching, and the itching scores were all above II degree, with obvious itching or severe itching.

[0127] As can be seen from Table 3, the pain scores of the patients using the wet wipes obtained in Examples 1-4 of the present invention were all below 3 points, showing mild pain, mostly intermittent pain, which did not affect normal life, and more than 60% of the patients had no pain. In Comparative Examples 1-6, the patients experienced pain, and the pain scores were above 3 points. In each comparative example, at least one patient reported a pain score of more than 5 points, which was relatively painful and could be continuous, but did not significantly affect normal life. Some patients reported that the pain scores could even reach 6 or 7 points.

[0128] The analgesic and antipruritic composition of the present invention has the following effects: witch hazel has astringent, anti-allergic and calming effects; Panax notoginseng extract has hemostatic, anti-inflammatory and analgesic effects; honeysuckle extract has the effects of dissipating dampness, reducing swelling, dissipating toxins and antibacterial and anti-inflammatory effects; chamomile extract has the effects of soothing, analgesic and strengthening tissues to eliminate edema; menthol and menthol lactate have the effects of cooling, relieving itching and alleviating pain; allantoin has the effects of softening tissues and promoting wound healing, so that the first active ingredient, the second active ingredient, the third active ingredient and the fourth active ingredient cooperate with each other to improve the antipruritic and analgesic effects. The wet wipes formed by the analgesic and antipruritic combination of the present invention can be packaged in a single piece and are easy to carry; deep cleaning can also be achieved without water washing conditions.

[0129] Therefore, the present invention effectively overcomes various shortcomings in the prior art and has high industrial utilization value.

[0130] The above is only a preferred embodiment of the present invention, and is not any formal or substantial limitation of the present invention. It should be pointed out that ordinary technicians in this technical field can make several improvements and supplements without departing from the method of the present invention, and these improvements and supplements should also be regarded as the protection scope of the present invention. Any technician familiar with this profession, without departing from the spirit and scope of the present invention, can make some changes, modifications and evolutions of the technical content disclosed above, which are equivalent embodiments of the present invention; at the same time, any changes, modifications and evolutions of any equivalent changes made to the above embodiments based on the essential technology of the present invention are still within the scope of the technical solution of the present invention.

Claims

1. A pain-relieving and antipruritic composition suitable for patients with anorectal diseases, characterized in that: The composition consists of a first active ingredient, a second active ingredient, a third active ingredient and a fourth active ingredient, as well as a bactericide, a preservative, a moisturizer, a solubilizer, a defoaming agent and a surfactant; The first active ingredient is Hamamelis virginiana extract; The second active ingredient is an anti-allergic agent, which is a mixture of Panax notoginseng extract, chamomile extract and honeysuckle extract, and the mass ratio of the Panax notoginseng extract, chamomile extract and honeysuckle extract is (1.5-8): (2-10): 1; The third active ingredient is a cooling agent, and the cooling agent is selected from one or two of menthol and menthol lactate; The fourth active ingredient is allantoin; The mass ratio of the first active ingredient, the second active ingredient, the third active ingredient and the fourth active ingredient is (10-30): (5-15): (1-3): (2-4); The content of the bactericidal disinfectant is 1 to 5% based on the total mass of the composition; The content of the preservative is 2 to 10% based on the total mass of the composition; Based on the total mass of the composition, the content of the moisturizing agent is 10 to 30%; Based on the total mass of the composition, the content of the solubilizer is 1 to 10%; Based on the total mass of the composition, the content of the defoaming agent is 0.01% to 0.5%; Based on the total mass of the composition, the content of the surfactant is 0.5-2%; The bactericidal disinfectant is selected from one or both of benzalkonium chloride and didecyldimethylammonium chloride; The preservative is selected from one or both of phenoxyethanol and iodopropynyl butyl carbamate; The moisturizer is selected from one or more of ethylhexylglycerin, trimethylglycine, propylene glycol and betaine; The solubilizing agent is selected from one or more of Tween 20, PEG-20 hydrogenated castor oil, PEG-40 hydrogenated castor oil and PEG-60 hydrogenated castor oil; The defoaming agent is selected from silicone defoaming agents; the surfactant is selected from cetylpyridinium chloride.

2. A solution for relieving pain and itching for patients with anorectal diseases, characterized in that: Prepared by dissolving the composition as claimed in claim 1 in water, The first active ingredient accounts for 2-3% of the total mass of the solution; The second active ingredient accounts for 1 to 1.5% of the total mass of the solution; The third active ingredient accounts for 0.2-0.6% of the total mass of the solution; The fourth active ingredient accounts for 0.3-0.5% of the total mass of the solution.

3. The solution according to claim 2, characterized in that Include at least one of the following technical features: B1) The bactericidal disinfectant accounts for 0.1-0.3% of the total mass of the solution; B2) The preservative accounts for 0.1-0.6% of the total mass of the solution; B3) The humectant accounts for 0.4-1.2% of the total mass of the solution; B4) the solubilizing agent accounts for 0.1 to 0.6% of the total mass of the solution; B5) The defoaming agent accounts for 0.001% to 0.01% of the total mass of the solution; B6) The surfactant accounts for 0.01% to 0.1% of the total mass of the solution; B7) The solution further comprises a pH adjuster, and the pH adjuster is used to adjust the pH value of the solution to 4.5-6.

7.

4. The method for preparing the solution according to claim 3, characterized in that: These include: 1) Mix water and defoamer according to the raw material ratio to obtain a primary mixed liquid; 2) mixing the preservative, the moisturizer, the third active ingredient, and the solubilizer with the primary mixed solution to obtain a secondary mixed solution; 3) Mixing the surfactant, the bactericide and disinfectant, the first active ingredient, the second active ingredient and the fourth active ingredient with the secondary mixed liquid, and adjusting the pH value with a pH adjuster to obtain the solution.

5. Use of the composition according to claim 1 or the solution according to claim 2 or 3 as a raw material in the preparation of wet wipes.

6. A wet wipe suitable for patients with anorectal diseases, characterized in that: The wet wipes include the composition according to claim 1 or the solution according to claim 2 or 3 and a wet wipes carrier.

7. The wet wipes according to claim 6, characterized in that: The wet wipes carrier is any one of non-woven fabric, cotton cloth, gauze and flushable paper.

8. The wet wipes according to claim 6, characterized in that: The mass ratio of the solution to the wet wipes carrier is (1-3):1.

Images